PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading
provider of drug development services to branded pharmaceutical,
biotechnology, generic drug and medical device companies, today
reported GAAP net earnings from continuing operations for its third
quarter ended September 30, 2006 of $3.0 million or $0.16 per
diluted share. �PharmaNet Development Group, Inc. had another solid
quarter resulting from excellent late stage revenue growth,
partially offset by lower revenues from the early stage segment,�
commented Jeffrey P. McMullen, president and chief executive
officer. �In addition to strong operational performance, we
recently achieved two major financial objectives with the amendment
of the credit facility and the execution of the agreement for the
sale and subsequent lease of the Quebec City site.� Basis of
presentation Due to the Company's decision to discontinue certain
operations earlier this year all financial results for the periods
presented reflect the Company's continuing operations only, unless
otherwise stated. To better reflect ongoing operations for
investors for the periods presented Adjusted (non-GAAP) results are
used throughout this press release and the accompanying tables. The
three months ended September 30, 2006 adjusted financial results
exclude the following costs: a) non-cash amortization ($0.7
million) and b) non-cash compensation expense resulting from the
adoption of SFAS 123(R) ($0.1 million). The Company adopted SFAS
No. 123(R), Share Based Payment, on January 1, 2006. A
reconciliation of GAAP results to Adjusted (non-GAAP) results can
be found in the unaudited financial tables included in this press
release. Third Quarter 2006 Financial Summary GAAP Direct revenue,
which does not include reimbursed out-of-pocket expenses, increased
5.7% to $76.0 million compared to $71.9 million in the third
quarter of 2005 primarily due to higher late stage revenues, offset
partly by lower early stage revenues. GAAP corporate expenses
increased to $5.0 million in third quarter 2006 compared to $3.2
million in third quarter 2005. Adjusted corporate expenses
increased to $4.9 million in the third quarter of 2006 from $3.2
million in the third quarter of 2005 primarily due to the non-cash
amortization of restricted stock units (RSUs), higher legal and
professional fees, increased bonus and compensation expense
resulting from organizational changes and the additional costs
relating to the Company name change. GAAP operating margin was 7.8%
in the third quarter 2006 compared with 16.2% in the third quarter
2005. Adjusted operating margin for the third quarter 2006
decreased to 8.9% from 17.6% in the third quarter of 2005 primarily
due to lower direct revenues in the early stage segment, continued
investment in early stage clinical and laboratory facilities and
higher corporate expenses. GAAP net earnings were $3.0 million in
the third quarter 2006 compared to $7.1 million in the third
quarter 2005. Adjusted net earnings for the third quarter of 2006
were approximately $3.7 million compared to $8.0 million for the
third quarter of 2005 primarily due to lower profits in the early
stage segment and increased corporate expenses partly offset by
increased profitability in the late stage segment. The Company�s
backlog increased sequentially to $357.0 million at September 30,
2006 from $353.5 million at June 30, 2006. Backlog consists of
anticipated direct revenue from signed contracts and letters of
intent that either have not started or are in process and have not
been completed. The combined book-to-bill ratio was 1.05:1. Cash,
cash equivalents, and investments in marketable securities at
September 30, 2006 were $53.8 million compared to $59.6 million at
June 30, 2006. In October 2006, the Company received approximately
$9.9 million in cash proceeds from the sale of the new Anapharm
Quebec City headquarters currently under construction. Net cash
provided by operating activities from continuing operations was
$3.6 million. Capital expenditures were $7.8 million, depreciation
was $2.8 million and amortization was $0.7 million in the third
quarter 2006 compared with $2.8 million, $2.5 million and $1.0
million, respectively, in the third quarter 2005. Included in the
$7.8 million is $4.4 million related to the construction of the new
Quebec City facility. Net Days Sales Outstanding (DSO) for
continuing operations, which includes accounts receivable and
unbilled services less current and long-term advanced billings,
were 31 days at September 30, 2006, reflecting a more normalized
level, compared with 14 days at June 30, 2006. The Company�s
effective tax rate in the quarter was 14.4% compared to 14.1% in
the third quarter of 2005. For the segment financial results
provided below, the Company has excluded an allocation of corporate
expenses related to certain adjusted selling, general and
administrative ("SG&A") expenses. Early Stage PharmaNet
Development Group, Inc.�s early stage segment primarily includes
the areas of Phase I clinical trials, support services and
bioanalytical services. For the early stage segment, GAAP direct
revenue, which does not include reimbursed out-of-pocket expenses,
was approximately $25.9 million in the third quarter 2006 compared
to approximately $31.4 million in the third quarter 2005 primarily
due to lower pricing and volume resulting from a more competitive
market environment. Early stage segment GAAP operating margins
decreased to 15.4% in the third quarter 2006 compared to 30.0% in
the third quarter 2005. Early stage segment adjusted operating
margins decreased to 15.9% in the third quarter 2006 compared to
31.0% in the third quarter 2005 primarily due to lower direct
revenues while maintaining the existing operational infrastructure.
The backlog for the early stage segment increased 22% to
approximately $37.6 million from $30.8 million reported at June 30,
2006 due to new generic, Phase I and bioanalytical business. The
construction plan is in place and on schedule for the new Quebec
City facility, which will house the staff and operations of the two
existing facilities that comprise the Anapharm headquarters. As
previously disclosed, the Company recently executed an agreement
for the sale and subsequent lease of the Quebec City site. The
Company continues to expect to occupy the facility in the second
quarter 2007. The Company is completing the leasehold improvements
at its Toronto site which will house clinical facilities. Based on
forecasted operating levels, the Company continues to assess the
time at which to commence operations in this location. Late Stage
PharmaNet Development Group, Inc.�s late stage segment primarily
conducts Phase II through IV clinical trials, data management and
biostatistics, medical and scientific affairs, regulatory affairs
and submissions, and provides software tools and services for use
in clinical trials. For the late stage segment, GAAP direct
revenue, which does not include reimbursed out-of-pocket expenses,
reached record levels increasing 23.8% to $50.1 million in the
third quarter 2006 compared to $40.5 million, in the third quarter
2005. Late stage segment GAAP operating margins were 13.9% in the
third quarter 2006 compared to 13.5% in the third quarter 2005.
Late stage segment adjusted operating margins were 15.1% in the
third quarter 2006 compared to 15.2% in the third quarter 2005. The
backlog for the late stage segment is approximately $319.4 million
compared to $322.7 million reported at June 30, 2006. Discontinued
operations The Company has a remaining balance of expected cash
costs relating to discontinued operations, totaling $3.6 million,
for demolition and asbestos remediation, severance, contracted
services and healthcare costs. The Company continues to proceed
toward demolition of the building and is assessing options with
respect to the sale of the land. Guidance For continuing operations
in the fourth quarter 2006, the Company expects direct revenues to
be in the range of $68.1 - $74.3 million, adjusted pre-tax earnings
to be in the range of $3.2 - $5.2 million, adjusted fully diluted
EPS of $0.16 - $0.22, capital expenditures to be in the range of
$4.0 - $5.0 million, depreciation to be in the range of $2.8 - $3.1
million, amortization to be approximately $0.7 million, and the tax
rate to be in the range of 10% to 20%. The Company expects to
provide guidance for 2007 in its fourth quarter and year-end 2006
earnings press release. Conference Call and Webcast A conference
call and webcast to discuss the third quarter financial results
will be held on Thursday, November 2, 2006 at 8:30 a.m., Eastern
Time. Dial-in: (866) 831-6272 for U.S. (617) 213-8859 for
International Pass code: 24262818 Dial-in Replay: (888) 286-8010
for U.S. (617) 801-6888 for International Pass code: 94602754 The
dial-in replay will be available approximately two hours after the
call through Thursday, November 9, 2006. Webcast: Please visit
www.pharmanet.com and select the investor tab to access the
webcast. The archived webcast will be available for approximately
thirty (30) days following the conference call. Non-GAAP Financial
Measures This press release contains non-GAAP financial measures,
which exclude, among other items, amortization of
acquisition-related intangible assets, non-recurring charges
related to financing, and non-cash impairment charges. PDGI
excludes these items from the non-GAAP financial measures because
they are outside of its operations and are a useful indicator,
which allows management to monitor PDGI�s underlying business
performance. Non-GAAP results also allow investors to compare the
reported GAAP results and the non-GAAP First Call consensus
estimate and to compare the Company�s operations against the
financial results of other companies in the industry. The non-GAAP
financial measures included in this press release should not be
considered superior to or a substitute for results of operations
prepared in accordance with GAAP. Reconciliations of the non-GAAP
financial measures used in this press release to the most directly
comparable GAAP financial measures are set forth in the text of,
and the accompanying tables to, this press release, and can also be
found on the Company�s website. About PharmaNet Development Group,
Inc. PharmaNet Development Group, Inc. is an international drug
development services company offering a comprehensive range of
clinical development, clinical and bioanalytical laboratory, and
consulting services to the branded pharmaceutical, biotechnology,
generic drug and medical device industries. PharmaNet Development
Group, Inc. has more than 30 offices, facilities and laboratories
with more than 2,000 employees strategically located throughout the
world. For more information, visit the Company's website at
http://www.pharmanet.com. Forward-Looking Statements Certain
statements made in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Additionally words such as "seek,"
"intend," "believe," "plan," "estimate," "expect," "anticipate" and
other similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include, but are not limited to,
industry trends and information; whether adverse publicity relating
to the Company�s discontinued Florida operations causes clients to
select competitors, not only for early stage branded clinical
trials but also for other aspects of the Company�s business; its
ability to comply with the timeline agreed upon in the settlement
reached with the Miami-Dade County Unsafe Structures Board and any
related fines or expenses if we are unsuccessful complying with
such timeline; the associated costs and expenses with discontinuing
the Company's operations in Florida, including the potential costs
of the demolition of the Miami facility; the Company's ability to
determine its impairment charges and costs of discontinued
operations; whether the Company will achieve its estimated value
for its Miami property; developments with respect to the SEC's
inquiry and securities class action lawsuits and derivative
lawsuits; the Company�s ability to successfully achieve and manage
the technical requirements of specialized clinical trial services,
while complying with applicable rules and regulations; regulatory
changes; changes affecting the clinical research industry; a
reduction of outsourcing by pharmaceutical and biotechnology
companies; the Company�s ability to compete internationally in
attracting clients in order to develop additional business; the
Company�s evaluation of its backlog and the potential cancellation
of contracts; its ability to retain and recruit new employees; its
clients' ability to provide the drugs and medical devices used in
its clinical trials; the Company�s future stock price; its
assessment of its effective tax rate; the Company�s financial
guidance; our future effective tax rate; our anticipated 2006
capital expenditures; our 2006 costs of compliance of Section 404
of the Sarbanes-Oxley Act; our ability to remediate our material
weaknesses; the impact of foreign currency transaction costs and
the effectiveness of any hedging strategies that we implement; and
the national and international economic climate as it affects drug
development operations. Further information can be found in the
Company�s risk factors contained in its Annual Report on Form 10-K
for the year ended December 31, 2005, which were originally filed
as SFBC International (NASDAQ: SFCC) and its most recent Quarterly
Report on Form 10-Q. The Company does not undertake to update the
disclosures made herein, and you are urged to read our filings with
the Securities and Exchange Commission. PHARMANET DEVELOPMENT
GROUP, INC. AND SUBSIDIARIES Statement of Operations (Unaudited)
For the Three Months Ended September 30, 2006 and 2005 � (As
Revised) � � 2006� � 2005� REVENUE � � � � Direct revenue
76,018,774� 71,890,582� Reimbursed out-of-pockets � 27,235,490� �
21,852,492� TOTAL REVENUE � 103,254,264� � 93,743,074� COSTS AND
EXPENSES � � � � Direct costs 45,769,899� 40,099,096� Reimbursable
out-of-pocket expenses 27,235,490� 21,852,492� Selling, general and
administrative expenses 24,337,454� 20,166,287� Impairment of
goodwill -� -� Impairment of long-lived assets � -� � -� TOTAL
COSTS AND EXPENSES � 97,342,843� � 82,117,875� EARNINGS (LOSS) FROM
CONTINUING OPERATIONS � 5,911,421� � 11,625,199� OTHER INCOME
(EXPENSE) � � � � Interest income 153,557� 140,309� Interest
expense (1,676,517) (1,780,407) Foreign exchange transaction gain
(loss), net � (647,315) � (1,456,276) TOTAL OTHER INCOME (EXPENSE)
� (2,170,275) � (3,096,374) EARNINGS (LOSS) FROM CONTINUING
OPERATIONS BEFORE INCOME TAXES 3,741,146� 8,528,825� � � Income tax
(benefit) � 538,771� � 1,204,844� EARNINGS (LOSS) FROM CONTINUING
OPERATIONS BEFORE MINORITY INTEREST IN JOINT VENTURE � 3,202,375� �
7,323,981� Minority interest in joint venture � 222,835� � 192,590�
NET EARNINGS (LOSS) FROM CONTINUING OPERATIONS � 2,979,540� �
7,131,391� Earnings (loss) from discontinued operations, net of tax
� (3,242,289) � 2,030,825� NET EARNINGS (LOSS) � (262,749) �
9,162,216� � � � � � BASIC EARNINGS (LOSS) PER SHARE: � � � �
Continuing operations $0.16� $0.39� Discontinued operations ($0.17)
$0.11� Net earnings (loss) � ($0.01) � $0.50� DILUTED EARNINGS
(LOSS) PER SHARE: � � � � Continuing operations $0.16� $0.37�
Discontinued operations ($0.17) $0.11� Net earnings (loss) �
($0.01) � $0.48� NUMBER OF SHARES USED IN COMPUTING EARNINGS PER
SHARE: � � � Basic 18,348,322� 18,459,258� Diluted � 18,473,375� �
19,158,308� PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES
Reconciliation of GAAP Operating Margin for Continuing Operations
to Non-GAAP Operating Margins for Continuing Operations For the
Three and Nine Months Ended September 30, 2006 and 2005 � Three
Months Ended Nine Months Ended � � 2006� � 2005� � 2006� � 2005�
DIRECT REVENUE 76,018,774� � 71,890,582� � 223,280,143� �
193,053,706� � � � � � � � � � EARNINGS FROM CONTINUING OPERATIONS
GAAP 5,911,421� � 11,625,199� � 5,582,388� � 20,266,138� � � � � �
� � � � OPERATING MARGIN GAAP 7.8% � 16.2% � 2.5% � 10.5% � � � � �
� � � � ADD BACK: � � � � � � � FAS 123(R) expense 149,063� -�
958,515� -� Amortization of acquisition related intangibles
703,646� 993,798� 2,274,359� 3,031,317� Impairment of goodwill -� �
-� � 7,873,000� � -� NON-GAAP OPERATING EARNINGS 6,764,130� �
12,618,997� � 16,688,262� � 23,297,455� � � � � � � � � � NON-GAAP
OPERATING MARGIN 8.9% � 17.6% � 7.5% � 12.1% PHARMANET DEVELOPMENT
GROUP, INC. AND SUBSIDIARIES Statement of Operations (Unaudited)
For the Nine Months Ended September 30, 2006 and 2005 � (As
Revised)) � � 2006� � 2005� REVENUE � � � � Direct revenue
223,280,143� 193,053,706� Reimbursed out-of-pockets � 80,119,231� �
65,340,179� TOTAL REVENUE � 303,399,374� � 258,393,885� COSTS AND
EXPENSES � � � � Direct costs 135,884,050� 112,089,743�
Reimbursable out-of-pocket expenses 80,119,231� 65,340,179�
Selling, general and administrative expenses 73,940,705�
60,697,825� Impairment of goodwill 7,873,000� -� Impairment of
long-lived assets � -� � -� TOTAL COSTS AND EXPENSES � 297,816,986�
� 238,127,747� EARNINGS (LOSS) FROM CONTINUING OPERATIONS �
5,582,388� � 20,266,138� OTHER INCOME (EXPENSE) � � � � Interest
income 1,050,060� 694,641� Interest expense (6,432,619)
(10,344,371) Foreign exchange transaction gain (loss), net �
(3,002,126) � (678,259) TOTAL OTHER INCOME (EXPENSE) � (8,384,685)
� (10,327,989) EARNINGS (LOSS) FROM CONTINUING OPERATIONS BEFORE
INCOME TAXES (2,802,297) 9,938,149� � � Income tax (benefit) �
(5,874,452) � 1,131,324� EARNINGS (LOSS) FROM CONTINUING OPERATIONS
BEFORE MINORITY INTEREST IN JOINT VENTURE 3,072,155� 8,806,825� � �
Minority interest in joint venture � 516,798� � 366,855� NET
EARNINGS (LOSS) FROM CONTINUING OPERATIONS � 2,555,357� �
8,439,970� Earnings (loss) from discontinued operations, net of tax
� (26,667,552) � 12,865,324� NET EARNINGS (LOSS) � (24,112,195) �
21,305,294� � � � � � BASIC EARNINGS (LOSS) PER SHARE: � � � �
Continuing operations $0.14� $0.48� Discontinued operations ($1.47)
$0.73� Net earnings (loss) � ($1.33) � $1.21� DILUTED EARNINGS
(LOSS) PER SHARE: � � � � Continuing operations $0.14� $0.46�
Discontinued operations ($1.45) $0.71� Net earnings (loss) �
($1.31) � $1.17� NUMBER OF SHARES USED IN COMPUTING EARNINGS PER
SHARE: � � � Basic 18,150,182� 17,543,438� Diluted � 18,376,696� �
18,217,963� PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES
Reconciliation of GAAP Net Earnings for Continuing Operations to
Non-GAAP Net Earnings from Continuing Operations For the Three and
Nine Months Ended September 30, 2006 and 2005 � � Three Months
Ended Nine Months Ended September 30, September 30, September 30,
September 30, 2006� 2005� 2006� 2005� � Net earnings from
continuing operations GAAP 2,979,540� 7,131,391� 2,555,357�
8,439,970� � Add: Impairment of goodwill -� -� 7,873,000� -� � Add:
Non-recurring charge related to financing -� -� 1,214,306�
3,278,279� � Add: FAS 123R expense 149,063� -� 958,515� -� � Add:
Amortization of acquisition related intangibles 703,646� 993,798�
2,274,359� 3,031,317� � Subtotal 3,832,249� 8,125,189� 14,875,537�
14,749,566� � Less: Tax effect of non-GAAP adjustments (1)(2)(3)
122,790� 140,126� 4,207,249� 909,430� � Non-GAAP net earnings
3,709,459� 7,985,063� 10,668,288� 13,840,136� � Diluted non-GAAP
net earnings per share $0.20� $0.42� $0.58� $0.76� � Number of
shares used in computing diluted non-GAAP earnings per share
18,473,375� 19,158,308� 18,376,696� 18,217,963� � � (1) The revised
tax rate used for the nine months ended September 30, 2006 is
approximately a benefit of (17.5%) after taking into account
adjustments reflected in this summary. � (2) The revised tax rate
used for the nine months ended September 30, 2005 is approximately
12.6% after taking into account adjustments reflected in this
summary. � (3) The quarterly tax effect for 2006 and 2005 have been
tax effected at their respective quarterly tax rates. PHARMANET
DEVELOPMENT GROUP, INC. AND SUBSIDIARIES Summary of Operations of
Early and Late Stage Clinical Development Segments For the Three
and Nine Months Ended September 30, 2006 and 2005 � � Three Months
Ended Nine Months Ended September 30, September 30, September 30,
September 30, EARLY CLINICAL DEVELOPMENT � 2006� � 2005� � 2006� �
2005� � Direct revenues 25,909,168� 31,419,515� 76,692,015�
77,462,605� � GAAP operating earnings (loss) 3,991,997� 9,412,359�
(377,141) 15,598,571� � Amortization of intangibles 128,846�
315,746� 549,959� 1,017,358� � Non-GAAP operating earnings (loss)
4,120,843� 9,728,105� 172,818� 16,615,929� � GAAP operating margin
15.4% 30.0% -0.5% 20.1% � Non-GAAP operating margin 15.9% 31.0%
0.2% 21.5% � Three Months Ended Nine Months Ended September 30,
September 30, September 30, September 30, LATE CLINICAL DEVELOPMENT
� 2006� � 2005� � 2006� � 2005� � Direct revenues 50,109,606�
40,471,067� 146,588,128� 115,591,101� � GAAP operating earnings
(loss) 6,983,946� 5,454,775� 22,418,455� 12,694,977� � Amortization
of intangibles 574,800� 678,052� 1,724,400� 2,013,959� � Non-GAAP
operating earnings (loss) 7,558,746� 6,132,827� 24,142,855�
14,708,936� � GAAP operating margin 13.9% 13.5% 15.3% 11.0% �
Non-GAAP operating margin 15.1% 15.2% 16.5% 12.7% PHARMANET
DEVELOPMENT GROUP, INC. AND SUBSIDIARIES Selected Consolidated
Balance Sheet Information September 30, 2006 and 2005 � (Unaudited)
(As Revised) September 30, December 31, � � � � � � 2006� � 2005�
ASSETS � � � � � � � � Cash, equivalents and investments in
marketable securities from continuing operations 53,820,203�
37,413,251� Cash, equivalents and investments in marketable
securities from discontinued operations -� 1,421,451� Total cash,
equivalents, and investments in marketable securities 53,820,203�
38,834,702� � Accounts receivable from continuing operations
109,782,587� 91,446,190� Accounts receivable from discontinued
operations 6,289,490� 26,425,479� Accounts receivable 116,072,077�
117,871,669� � Current assets from continuing operations
180,061,293� 148,692,703� Current assets from discontinued
operations 6,397,498� 29,335,006� Total current assets 186,458,791�
178,027,709� � Fixed assets from continuing operations 61,796,913�
48,563,461� Fixed assets held available for sale from discontinued
operations 3,487,415� 24,701,651� Total fixed assets 65,284,328�
73,265,112� � Total assets from continuing operations 555,070,421�
514,328,567� Total assets from discontinued operations 9,884,913�
58,208,529� Total assets 564,955,334� 572,537,096� � � � � � � � �
� LIABILITIES AND STOCKHOLDERS' EQUITY � � � � Current liabilities
from continuing operations 125,070,285� 120,493,672� Current
liabilities from discontinued operations 5,624,726� 5,940,389�
Total current liabilities 130,695,011� 126,434,061� � Total
liabilities from continuing operations 292,629,463� 284,315,108�
Total liabilities from discontinued operations 5,642,726�
5,940,389� Total liabilities 298,272,189� 290,255,497� �
Stockholders' equity 266,683,145� 282,281,599� � Total liabilities
and stockholders' equity 564,955,334� 572,537,096� PharmaNet
Development Group, Inc. (NASDAQ: PDGI), a leading provider of drug
development services to branded pharmaceutical, biotechnology,
generic drug and medical device companies, today reported GAAP net
earnings from continuing operations for its third quarter ended
September 30, 2006 of $3.0 million or $0.16 per diluted share.
"PharmaNet Development Group, Inc. had another solid quarter
resulting from excellent late stage revenue growth, partially
offset by lower revenues from the early stage segment," commented
Jeffrey P. McMullen, president and chief executive officer. "In
addition to strong operational performance, we recently achieved
two major financial objectives with the amendment of the credit
facility and the execution of the agreement for the sale and
subsequent lease of the Quebec City site." Basis of presentation
Due to the Company's decision to discontinue certain operations
earlier this year all financial results for the periods presented
reflect the Company's continuing operations only, unless otherwise
stated. To better reflect ongoing operations for investors for the
periods presented Adjusted (non-GAAP) results are used throughout
this press release and the accompanying tables. The three months
ended September 30, 2006 adjusted financial results exclude the
following costs: a) non-cash amortization ($0.7 million) and b)
non-cash compensation expense resulting from the adoption of SFAS
123(R) ($0.1 million). The Company adopted SFAS No. 123(R), Share
Based Payment, on January 1, 2006. A reconciliation of GAAP results
to Adjusted (non-GAAP) results can be found in the unaudited
financial tables included in this press release. Third Quarter 2006
Financial Summary -- GAAP Direct revenue, which does not include
reimbursed out-of-pocket expenses, increased 5.7% to $76.0 million
compared to $71.9 million in the third quarter of 2005 primarily
due to higher late stage revenues, offset partly by lower early
stage revenues. -- GAAP corporate expenses increased to $5.0
million in third quarter 2006 compared to $3.2 million in third
quarter 2005. Adjusted corporate expenses increased to $4.9 million
in the third quarter of 2006 from $3.2 million in the third quarter
of 2005 primarily due to the non-cash amortization of restricted
stock units (RSUs), higher legal and professional fees, increased
bonus and compensation expense resulting from organizational
changes and the additional costs relating to the Company name
change. -- GAAP operating margin was 7.8% in the third quarter 2006
compared with 16.2% in the third quarter 2005. Adjusted operating
margin for the third quarter 2006 decreased to 8.9% from 17.6% in
the third quarter of 2005 primarily due to lower direct revenues in
the early stage segment, continued investment in early stage
clinical and laboratory facilities and higher corporate expenses.
-- GAAP net earnings were $3.0 million in the third quarter 2006
compared to $7.1 million in the third quarter 2005. Adjusted net
earnings for the third quarter of 2006 were approximately $3.7
million compared to $8.0 million for the third quarter of 2005
primarily due to lower profits in the early stage segment and
increased corporate expenses partly offset by increased
profitability in the late stage segment. -- The Company's backlog
increased sequentially to $357.0 million at September 30, 2006 from
$353.5 million at June 30, 2006. Backlog consists of anticipated
direct revenue from signed contracts and letters of intent that
either have not started or are in process and have not been
completed. The combined book-to-bill ratio was 1.05:1. -- Cash,
cash equivalents, and investments in marketable securities at
September 30, 2006 were $53.8 million compared to $59.6 million at
June 30, 2006. In October 2006, the Company received approximately
$9.9 million in cash proceeds from the sale of the new Anapharm
Quebec City headquarters currently under construction. -- Net cash
provided by operating activities from continuing operations was
$3.6 million. Capital expenditures were $7.8 million, depreciation
was $2.8 million and amortization was $0.7 million in the third
quarter 2006 compared with $2.8 million, $2.5 million and $1.0
million, respectively, in the third quarter 2005. Included in the
$7.8 million is $4.4 million related to the construction of the new
Quebec City facility. -- Net Days Sales Outstanding (DSO) for
continuing operations, which includes accounts receivable and
unbilled services less current and long-term advanced billings,
were 31 days at September 30, 2006, reflecting a more normalized
level, compared with 14 days at June 30, 2006. -- The Company's
effective tax rate in the quarter was 14.4% compared to 14.1% in
the third quarter of 2005. For the segment financial results
provided below, the Company has excluded an allocation of corporate
expenses related to certain adjusted selling, general and
administrative ("SG&A") expenses. Early Stage PharmaNet
Development Group, Inc.'s early stage segment primarily includes
the areas of Phase I clinical trials, support services and
bioanalytical services. For the early stage segment, GAAP direct
revenue, which does not include reimbursed out-of-pocket expenses,
was approximately $25.9 million in the third quarter 2006 compared
to approximately $31.4 million in the third quarter 2005 primarily
due to lower pricing and volume resulting from a more competitive
market environment. Early stage segment GAAP operating margins
decreased to 15.4% in the third quarter 2006 compared to 30.0% in
the third quarter 2005. Early stage segment adjusted operating
margins decreased to 15.9% in the third quarter 2006 compared to
31.0% in the third quarter 2005 primarily due to lower direct
revenues while maintaining the existing operational infrastructure.
The backlog for the early stage segment increased 22% to
approximately $37.6 million from $30.8 million reported at June 30,
2006 due to new generic, Phase I and bioanalytical business. The
construction plan is in place and on schedule for the new Quebec
City facility, which will house the staff and operations of the two
existing facilities that comprise the Anapharm headquarters. As
previously disclosed, the Company recently executed an agreement
for the sale and subsequent lease of the Quebec City site. The
Company continues to expect to occupy the facility in the second
quarter 2007. The Company is completing the leasehold improvements
at its Toronto site which will house clinical facilities. Based on
forecasted operating levels, the Company continues to assess the
time at which to commence operations in this location. Late Stage
PharmaNet Development Group, Inc.'s late stage segment primarily
conducts Phase II through IV clinical trials, data management and
biostatistics, medical and scientific affairs, regulatory affairs
and submissions, and provides software tools and services for use
in clinical trials. For the late stage segment, GAAP direct
revenue, which does not include reimbursed out-of-pocket expenses,
reached record levels increasing 23.8% to $50.1 million in the
third quarter 2006 compared to $40.5 million, in the third quarter
2005. Late stage segment GAAP operating margins were 13.9% in the
third quarter 2006 compared to 13.5% in the third quarter 2005.
Late stage segment adjusted operating margins were 15.1% in the
third quarter 2006 compared to 15.2% in the third quarter 2005. The
backlog for the late stage segment is approximately $319.4 million
compared to $322.7 million reported at June 30, 2006. Discontinued
operations The Company has a remaining balance of expected cash
costs relating to discontinued operations, totaling $3.6 million,
for demolition and asbestos remediation, severance, contracted
services and healthcare costs. The Company continues to proceed
toward demolition of the building and is assessing options with
respect to the sale of the land. Guidance For continuing operations
in the fourth quarter 2006, the Company expects -- direct revenues
to be in the range of $68.1 - $74.3 million, -- adjusted pre-tax
earnings to be in the range of $3.2 - $5.2 million, -- adjusted
fully diluted EPS of $0.16 - $0.22, -- capital expenditures to be
in the range of $4.0 - $5.0 million, -- depreciation to be in the
range of $2.8 - $3.1 million, -- amortization to be approximately
$0.7 million, -- and the tax rate to be in the range of 10% to 20%.
The Company expects to provide guidance for 2007 in its fourth
quarter and year-end 2006 earnings press release. Conference Call
and Webcast A conference call and webcast to discuss the third
quarter financial results will be held on Thursday, November 2,
2006 at 8:30 a.m., Eastern Time. -0- *T Dial-in: (866) 831-6272 for
U.S. (617) 213-8859 for International Pass code: 24262818 Dial-in
Replay: (888) 286-8010 for U.S. (617) 801-6888 for International
Pass code: 94602754 The dial-in replay will be available
approximately two hours after the call through Thursday, November
9, 2006. Webcast: Please visit www.pharmanet.com and select the
investor tab to access the webcast. The archived webcast will be
available for approximately thirty (30) days following the
conference call. *T Non-GAAP Financial Measures This press release
contains non-GAAP financial measures, which exclude, among other
items, amortization of acquisition-related intangible assets,
non-recurring charges related to financing, and non-cash impairment
charges. PDGI excludes these items from the non-GAAP financial
measures because they are outside of its operations and are a
useful indicator, which allows management to monitor PDGI's
underlying business performance. Non-GAAP results also allow
investors to compare the reported GAAP results and the non-GAAP
First Call consensus estimate and to compare the Company's
operations against the financial results of other companies in the
industry. The non-GAAP financial measures included in this press
release should not be considered superior to or a substitute for
results of operations prepared in accordance with GAAP.
Reconciliations of the non-GAAP financial measures used in this
press release to the most directly comparable GAAP financial
measures are set forth in the text of, and the accompanying tables
to, this press release, and can also be found on the Company's
website. About PharmaNet Development Group, Inc. PharmaNet
Development Group, Inc. is an international drug development
services company offering a comprehensive range of clinical
development, clinical and bioanalytical laboratory, and consulting
services to the branded pharmaceutical, biotechnology, generic drug
and medical device industries. PharmaNet Development Group, Inc.
has more than 30 offices, facilities and laboratories with more
than 2,000 employees strategically located throughout the world.
For more information, visit the Company's website at
http://www.pharmanet.com. Forward-Looking Statements Certain
statements made in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Additionally words such as "seek,"
"intend," "believe," "plan," "estimate," "expect," "anticipate" and
other similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include, but are not limited to,
industry trends and information; whether adverse publicity relating
to the Company's discontinued Florida operations causes clients to
select competitors, not only for early stage branded clinical
trials but also for other aspects of the Company's business; its
ability to comply with the timeline agreed upon in the settlement
reached with the Miami-Dade County Unsafe Structures Board and any
related fines or expenses if we are unsuccessful complying with
such timeline; the associated costs and expenses with discontinuing
the Company's operations in Florida, including the potential costs
of the demolition of the Miami facility; the Company's ability to
determine its impairment charges and costs of discontinued
operations; whether the Company will achieve its estimated value
for its Miami property; developments with respect to the SEC's
inquiry and securities class action lawsuits and derivative
lawsuits; the Company's ability to successfully achieve and manage
the technical requirements of specialized clinical trial services,
while complying with applicable rules and regulations; regulatory
changes; changes affecting the clinical research industry; a
reduction of outsourcing by pharmaceutical and biotechnology
companies; the Company's ability to compete internationally in
attracting clients in order to develop additional business; the
Company's evaluation of its backlog and the potential cancellation
of contracts; its ability to retain and recruit new employees; its
clients' ability to provide the drugs and medical devices used in
its clinical trials; the Company's future stock price; its
assessment of its effective tax rate; the Company's financial
guidance; our future effective tax rate; our anticipated 2006
capital expenditures; our 2006 costs of compliance of Section 404
of the Sarbanes-Oxley Act; our ability to remediate our material
weaknesses; the impact of foreign currency transaction costs and
the effectiveness of any hedging strategies that we implement; and
the national and international economic climate as it affects drug
development operations. Further information can be found in the
Company's risk factors contained in its Annual Report on Form 10-K
for the year ended December 31, 2005, which were originally filed
as SFBC International (NASDAQ: SFCC) and its most recent Quarterly
Report on Form 10-Q. The Company does not undertake to update the
disclosures made herein, and you are urged to read our filings with
the Securities and Exchange Commission. -0- *T PHARMANET
DEVELOPMENT GROUP, INC. AND SUBSIDIARIES Statement of Operations
(Unaudited) For the Three Months Ended September 30, 2006 and 2005
(As Revised) 2006 2005
----------------------------------------------------------------------
REVENUE
----------------------------------------------------------------------
Direct revenue 76,018,774 71,890,582 Reimbursed out-of-pockets
27,235,490 21,852,492
----------------------------------------------------------------------
TOTAL REVENUE 103,254,264 93,743,074
----------------------------------------------------------------------
COSTS AND EXPENSES
----------------------------------------------------------------------
Direct costs 45,769,899 40,099,096 Reimbursable out-of-pocket
expenses 27,235,490 21,852,492 Selling, general and administrative
expenses 24,337,454 20,166,287 Impairment of goodwill - -
Impairment of long-lived assets - -
----------------------------------------------------------------------
TOTAL COSTS AND EXPENSES 97,342,843 82,117,875
----------------------------------------------------------------------
EARNINGS (LOSS) FROM CONTINUING OPERATIONS 5,911,421 11,625,199
----------------------------------------------------------------------
OTHER INCOME (EXPENSE)
----------------------------------------------------------------------
Interest income 153,557 140,309 Interest expense (1,676,517)
(1,780,407) Foreign exchange transaction gain (loss), net (647,315)
(1,456,276)
----------------------------------------------------------------------
TOTAL OTHER INCOME (EXPENSE) (2,170,275) (3,096,374)
----------------------------------------------------------------------
EARNINGS (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
3,741,146 8,528,825
----------------------------------------------------------------------
Income tax (benefit) 538,771 1,204,844
----------------------------------------------------------------------
EARNINGS (LOSS) FROM CONTINUING OPERATIONS BEFORE MINORITY INTEREST
IN JOINT VENTURE 3,202,375 7,323,981
----------------------------------------------------------------------
Minority interest in joint venture 222,835 192,590
----------------------------------------------------------------------
NET EARNINGS (LOSS) FROM CONTINUING OPERATIONS 2,979,540 7,131,391
----------------------------------------------------------------------
Earnings (loss) from discontinued operations, net of tax
(3,242,289) 2,030,825
----------------------------------------------------------------------
NET EARNINGS (LOSS) (262,749) 9,162,216
----------------------------------------------------------------------
----------------------------------------------------------------------
BASIC EARNINGS (LOSS) PER SHARE:
----------------------------------------------------------------------
Continuing operations $0.16 $0.39 Discontinued operations ($0.17)
$0.11 Net earnings (loss) ($0.01) $0.50
----------------------------------------------------------------------
DILUTED EARNINGS (LOSS) PER SHARE:
----------------------------------------------------------------------
Continuing operations $0.16 $0.37 Discontinued operations ($0.17)
$0.11 Net earnings (loss) ($0.01) $0.48
----------------------------------------------------------------------
NUMBER OF SHARES USED IN COMPUTING EARNINGS PER SHARE:
----------------------------------------------------------------------
Basic 18,348,322 18,459,258 Diluted 18,473,375 19,158,308
----------------------------------------------------------------------
*T -0- *T PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES
Reconciliation of GAAP Operating Margin for Continuing Operations
to Non-GAAP Operating Margins for Continuing Operations For the
Three and Nine Months Ended September 30, 2006 and 2005 Three
Months Ended Nine Months Ended 2006 2005 2006 2005
----------------------------------------------------------------------
DIRECT REVENUE 76,018,774 71,890,582 223,280,143 193,053,706
----------------------------------------------------------------------
----------------------------------------------------------------------
EARNINGS FROM CONTINUING OPERATIONS GAAP 5,911,421 11,625,199
5,582,388 20,266,138
----------------------------------------------------------------------
----------------------------------------------------------------------
OPERATING MARGIN GAAP 7.8% 16.2% 2.5% 10.5%
----------------------------------------------------------------------
----------------------------------------------------------------------
ADD BACK:
----------------------------------------------------------------------
FAS 123(R) expense 149,063 - 958,515 - Amortization of acquisition
related intangibles 703,646 993,798 2,274,359 3,031,317 Impairment
of goodwill - - 7,873,000 -
----------------------------------------------------------------------
NON-GAAP OPERATING EARNINGS 6,764,130 12,618,997 16,688,262
23,297,455
----------------------------------------------------------------------
----------------------------------------------------------------------
NON-GAAP OPERATING MARGIN 8.9% 17.6% 7.5% 12.1%
----------------------------------------------------------------------
*T -0- *T PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES
Statement of Operations (Unaudited) For the Nine Months Ended
September 30, 2006 and 2005 (As Revised)) 2006 2005
----------------------------------------------------------------------
REVENUE
----------------------------------------------------------------------
Direct revenue 223,280,143 193,053,706 Reimbursed out-of-pockets
80,119,231 65,340,179
----------------------------------------------------------------------
TOTAL REVENUE 303,399,374 258,393,885
----------------------------------------------------------------------
COSTS AND EXPENSES
----------------------------------------------------------------------
Direct costs 135,884,050 112,089,743 Reimbursable out-of-pocket
expenses 80,119,231 65,340,179 Selling, general and administrative
expenses 73,940,705 60,697,825 Impairment of goodwill 7,873,000 -
Impairment of long-lived assets - -
----------------------------------------------------------------------
TOTAL COSTS AND EXPENSES 297,816,986 238,127,747
----------------------------------------------------------------------
EARNINGS (LOSS) FROM CONTINUING OPERATIONS 5,582,388 20,266,138
----------------------------------------------------------------------
OTHER INCOME (EXPENSE)
----------------------------------------------------------------------
Interest income 1,050,060 694,641 Interest expense (6,432,619)
(10,344,371) Foreign exchange transaction gain (loss), net
(3,002,126) (678,259)
----------------------------------------------------------------------
TOTAL OTHER INCOME (EXPENSE) (8,384,685) (10,327,989)
----------------------------------------------------------------------
EARNINGS (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(2,802,297) 9,938,149
----------------------------------------------------------------------
Income tax (benefit) (5,874,452) 1,131,324
----------------------------------------------------------------------
EARNINGS (LOSS) FROM CONTINUING OPERATIONS BEFORE MINORITY INTEREST
IN JOINT VENTURE 3,072,155 8,806,825
----------------------------------------------------------------------
Minority interest in joint venture 516,798 366,855
----------------------------------------------------------------------
NET EARNINGS (LOSS) FROM CONTINUING OPERATIONS 2,555,357 8,439,970
----------------------------------------------------------------------
Earnings (loss) from discontinued operations, net of tax
(26,667,552) 12,865,324
----------------------------------------------------------------------
NET EARNINGS (LOSS) (24,112,195) 21,305,294
----------------------------------------------------------------------
----------------------------------------------------------------------
BASIC EARNINGS (LOSS) PER SHARE:
----------------------------------------------------------------------
Continuing operations $0.14 $0.48 Discontinued operations ($1.47)
$0.73 Net earnings (loss) ($1.33) $1.21
----------------------------------------------------------------------
DILUTED EARNINGS (LOSS) PER SHARE:
----------------------------------------------------------------------
Continuing operations $0.14 $0.46 Discontinued operations ($1.45)
$0.71 Net earnings (loss) ($1.31) $1.17
----------------------------------------------------------------------
NUMBER OF SHARES USED IN COMPUTING EARNINGS PER SHARE:
----------------------------------------------------------------------
Basic 18,150,182 17,543,438 Diluted 18,376,696 18,217,963
----------------------------------------------------------------------
*T -0- *T PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES
Reconciliation of GAAP Net Earnings for Continuing Operations to
Non- GAAP Net Earnings from Continuing Operations For the Three and
Nine Months Ended September 30, 2006 and 2005 Three Months Ended
Nine Months Ended September 30, September 30, September 30,
September 30, 2006 2005 2006 2005 Net earnings from continuing
operations GAAP 2,979,540 7,131,391 2,555,357 8,439,970 Add:
Impairment of goodwill - - 7,873,000 - Add: Non- recurring charge
related to financing - - 1,214,306 3,278,279 Add: FAS 123R expense
149,063 - 958,515 - Add: Amortization of acquisition related
intangibles 703,646 993,798 2,274,359 3,031,317 Subtotal 3,832,249
8,125,189 14,875,537 14,749,566 Less: Tax effect of non-GAAP
adjustments (1)(2)(3) 122,790 140,126 4,207,249 909,430 Non-GAAP
net earnings 3,709,459 7,985,063 10,668,288 13,840,136 Diluted non-
GAAP net earnings per share $0.20 $0.42 $0.58 $0.76 Number of
shares used in computing diluted non- GAAP earnings per share
18,473,375 19,158,308 18,376,696 18,217,963 (1) The revised tax
rate used for the nine months ended September 30, 2006 is
approximately a benefit of (17.5%) after taking into account
adjustments reflected in this summary. (2) The revised tax rate
used for the nine months ended September 30, 2005 is approximately
12.6% after taking into account adjustments reflected in this
summary. (3) The quarterly tax effect for 2006 and 2005 have been
tax effected at their respective quarterly tax rates. *T -0- *T
PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES Summary of
Operations of Early and Late Stage Clinical Development Segments
For the Three and Nine Months Ended September 30, 2006 and 2005
Three Months Ended Nine Months Ended September 30, September 30,
September 30, September 30, EARLY CLINICAL DEVELOPMENT 2006 2005
2006 2005
----------------------------------------------------------------------
Direct revenues 25,909,168 31,419,515 76,692,015 77,462,605 GAAP
operating earnings (loss) 3,991,997 9,412,359 (377,141) 15,598,571
Amortization of intangibles 128,846 315,746 549,959 1,017,358
Non-GAAP operating earnings (loss) 4,120,843 9,728,105 172,818
16,615,929 GAAP operating margin 15.4% 30.0% -0.5% 20.1% Non-GAAP
operating margin 15.9% 31.0% 0.2% 21.5% Three Months Ended Nine
Months Ended September 30, September 30, September 30, September
30, LATE CLINICAL DEVELOPMENT 2006 2005 2006 2005
----------------------------------------------------------------------
Direct revenues 50,109,606 40,471,067 146,588,128 115,591,101 GAAP
operating earnings (loss) 6,983,946 5,454,775 22,418,455 12,694,977
Amortization of intangibles 574,800 678,052 1,724,400 2,013,959
Non-GAAP operating earnings (loss) 7,558,746 6,132,827 24,142,855
14,708,936 GAAP operating margin 13.9% 13.5% 15.3% 11.0% Non-GAAP
operating margin 15.1% 15.2% 16.5% 12.7% *T -0- *T PHARMANET
DEVELOPMENT GROUP, INC. AND SUBSIDIARIES Selected Consolidated
Balance Sheet Information September 30, 2006 and 2005 (Unaudited)
(As Revised) September 30, December 31, 2006 2005
----------------------------------------------------------------------
ASSETS
----------------------------------------------------------------------
Cash, equivalents and investments in marketable securities from
continuing operations 53,820,203 37,413,251 Cash, equivalents and
investments in marketable securities from discontinued operations -
1,421,451 ------------- ------------ Total cash, equivalents, and
investments in marketable securities 53,820,203 38,834,702 Accounts
receivable from continuing operations 109,782,587 91,446,190
Accounts receivable from discontinued operations 6,289,490
26,425,479 ------------- ------------ Accounts receivable
116,072,077 117,871,669 Current assets from continuing operations
180,061,293 148,692,703 Current assets from discontinued operations
6,397,498 29,335,006 ------------- ------------ Total current
assets 186,458,791 178,027,709 Fixed assets from continuing
operations 61,796,913 48,563,461 Fixed assets held available for
sale from discontinued operations 3,487,415 24,701,651
------------- ------------ Total fixed assets 65,284,328 73,265,112
Total assets from continuing operations 555,070,421 514,328,567
Total assets from discontinued operations 9,884,913 58,208,529
------------- ------------ Total assets 564,955,334 572,537,096
----------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
----------------------------------------------------------------------
Current liabilities from continuing operations 125,070,285
120,493,672 Current liabilities from discontinued operations
5,624,726 5,940,389 ------------- ------------ Total current
liabilities 130,695,011 126,434,061 Total liabilities from
continuing operations 292,629,463 284,315,108 Total liabilities
from discontinued operations 5,642,726 5,940,389 -------------
------------ Total liabilities 298,272,189 290,255,497
Stockholders' equity 266,683,145 282,281,599 Total liabilities and
stockholders' equity 564,955,334 572,537,096 *T
Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jul 2023 to Jul 2024